Supply Issues Heraeus Medical Bone Cement Products (ICN 3261)

Change:

• Johnson & Johnson additional stock:
  • Johnson & Johnson CMW Smartset GHV Gentamicin 40g Bone Cement additional stock is now available to order.
  • This is one of the two identified alternatives to the unavailable Heraeus bone cement products.
  • Johnson & Johnson has requested that customers place all orders for this stock by ordering packs of 10 using:
    • FQT85035 – Antibiotic SMARTSET GHV GENTAMICIN 40G BONE CEMENT.
  • Submit a demand capture form for any stock you wish to order.
  • Trusts should consider the use of this product along with the Zimmer Biomet High Fatigue G to meet the gap in stock availability from Heraeus.
  • Smartset is a cold chain product, so will be delivered via our eDirect route.

• Zimmer Biomet training video:
  • Zimmer Biomet has produced a video to support NHS trusts with training on how to prepare and use its High Fatigue G bone cement, the other identified alternative.
  • See our Useful Links section to view the video.
  • Company representatives are also available to support face-to-face training.

• Ordering:
  • If you are ordering daily, please ensure you are placing the order for requisition points that are open for an everyday delivery.

• Bank holiday ordering:
  • To support customers during the upcoming Bank Holiday periods, daily order thresholds for either product will be increased by 20% in advance of each holiday closure. This temporary uplift helps accommodate additional demand and ensures continuity of supply on non-delivery days:
    • Easter – Thresholds increased from Monday 23 March 2026
    • May Day Bank Holiday – Thresholds increased from Monday 27 April 2026
    • Spring Bank Holiday – Thresholds increased from Monday 18 May 2026.
  • To do this, you should increase your order volumes for daily ordering or amend the quantity if you have standing orders set up.
  • All orders are subject to demand management and can only be fulfilled where stock is available. Please ensure orders remain in line with BAU levels, plus the 20% daily threshold increase for the bank holiday.

Next steps:

• See our Useful Links section to view the Zimmer Biomet High Fatigue G training video.
• See our Downloads ▼ section to read a customer briefing which sets out the products available and the way to order them, including demand capture and escalation processes. Please ensure you follow these processes.
• See our Downloads ▼ section to find a series of information sheets to support clinical decision making over the use of the alternative products.
• Complete a demand capture form to inform us of your intended stock requirements.
• See our Downloads ▼ section to obtain a demand capture or escalation form
• Check this ICN regularly for further updates.
• If you have any questions, please speak to your customer service advisor or your ICS Manager for further support.

Change

• The IT issues which were preventing the National Product Code FQT85055 for Zimmer Biomet High Fatigue G bone cement showing in our online catalogue have been resolved.
• We are aware some trusts order bone cement products via your pharmacy teams. We will require those teams to place orders for products in line with the usual demand management route as we are unable to consolidate these to enable weekly orders to be placed.

Impact

• Orders for FQT85055 can now be placed as normal via the catalogue again.
• Your pharmacy teams should place orders using the guidance in the customer briefing in our downloads section.

Next steps

• See our Downloads ▼ section to read a customer briefing which sets out the products available and the way to order them, including demand capture and escalation processes. Please ensure you follow these processes.
• See our Downloads ▼ section to find a series of information sheets to support clinical decision making over the use of the alternative products.
• Check this ICN regularly for further updates.
• See our Downloads ▼ section to obtain a demand capture or escalation form.
• If you have any questions, please speak to your customer service advisor or your ICS Manager for further support.

Change

• We’re experiencing an IT issue that is preventing the National Product Code FQT85055 for Zimmer Biomet High Fatigue G bone cement showing in our online catalogue today (Thursday 26 February 2026).
• Please be assured that stock is available.

Impact

• This will impact your ability to place orders.
• If you have a standing order in place and were expecting a delivery on Monday 2 March 2026 that order may have been affected.

Next steps

• To order the product today, please contact your Customer Service Advisor, who will process the order on your behalf.
• If you have a standing order and were expecting a delivery on Monday 2 March 2026, please also get in touch with your Customer Service Advisor so they can confirm that your order has not been affected and reorder for you.
• We expect the code will be visible in our catalogue again from tomorrow (Friday 27 February 2026).
• A further update will be provided tomorrow (Friday 27 February 2026).

Change

• Two clinically assured alternative products have been identified as alternatives for high viscosity bone cement with gentamicin – Zimmer Biomet High Fatigue G and Johnson & Johnson CMW Smartset GHV Gentamicin.
• The following National Product Code (NPC) will be available to order through our online catalogue only from Wednesday 25 February 2026 for the Zimmer Biomet High Fatigue G product:
  • FQT85055
  • FQT85054 will be available from 10 March 2026.
• The NPCs for the J&J CMW Smartset GHV Gentamicin products will be available from early March 2026. This ICN will be updated when they are available to order via our online catalogue.

Impact

• We have Zimmer Biomet stock available in addition to normal supplies from suppliers other than Heraeus. Please order at normal levels. Stock held by both NHS Supply Chain and individual suppliers will be demand managed to prevent over ordering.
• Heraeus is continuing to allocate the small amount of available stock it has on a back-order basis. They do not currently have stock to facilitate any new orders.
• On our customer webinar several questions were asked around ordering processes via pharmacy teams. These are being reviewed and we will update this ICN once our teams have considered how ordering processes can be amended to support this.

Next steps

• See our Downloads ▼ section to read a customer briefing which sets out the products available and the way to order them, including demand capture and escalation processes. Please ensure you follow these processes.
• See our Downloads ▼ section to find a series of information sheets to support clinical decision making over the use of the alternative products.
• Follow the national guidance issued by NHS England and the British Orthopaedic Association to support local decision making on stock availability and elective procedures.
• Review the revised product listing in our downloads section which has further information on the impacted products and alternative products that could be used.
• See our Downloads ▼ section to obtain a demand capture or escalation form.
• Place orders daily to ensure uninterrupted supply
• Consider utilising the standing order function which is available in our online catalogue.
• Check this ICN regularly for further updates.
• If you have any questions, please speak to your customer service advisor or your ICS Manager for further support.

• National guidance for clinicians on how to handle the impact of the supply disruption has been issued jointly by the NHS England National Clinical Directors and the British Orthopaedic Association.
• See our Downloads ▼ section to read the national guidance and suggested alternative products.

Next steps

• Trusts and ICBs should follow the national guidance issued by NHS England and the British Orthopaedic Association to support local decision making and the national stock position.
• Review the product listing in our downloads section which has further information on the impacted products.
• Check this ICN regularly for further updates.
• If you have any questions, please speak to your customer service advisor or your ICS Manager for further support.

• Two further product codes are impacted:
  • FQT85017 and FQT85018.
• 17 codes are now affected in total.
• The product listing has now been updated with further information on the affected products.
• See our Downloads ▼ section to view the updated product listing.
• Bone Cement is distributed via temperature controlled cold chain logistics, which is required to ensure the stability of the product. NHS Supply Chain is not commissioned to provide cold chain services so we cannot bring stock into our warehouse network or apply conventional demand management.
• We are working closely with Heraeus and alternative suppliers to secure available stock. Suppliers with stock are being asked to apply demand management measures to support the national stock position. Use will be prioritised in line with NHS England pathway guidance, with a particular emphasis on prioritising trauma care.

Change:

• This impacts 15 Heraeus Medical product codes:
  • FQQ1001, FQQ388, FQQ113, FJI4643, FQQ1061, FQQ1151, FQQ1111, FQQ1131, FQQ1101, FQQ1081, FQQ1091, FQQ1021, FQQ1031, FQT85049 and FQQ1011.
• The supply issue is due to supplier manufacturing issues.

Impact:

• We are engaging with alternative suppliers in this market and are identifying their ability to provide alternative products that are compliant routes to market in this period of disruption. This will be communicated as soon as possible via a product listing update to this ICN.
• Heraeus Medical have indicated this will take a minimum of two months to return to full production. Firmer timeframes will be shared as the supplier response plan is determined.

Next Steps:                   

• Regular updates and trust action will be shared on this ICN.
• See our Downloads ▼ section to view the product listing and the customer letter from Heraeus Medical about the supply disruption.
• Please ensure Clinical teams and Orthopaedic teams within your trust are made aware of this issue.
• Trusts should start to consider the impact to their trust and review local decision-making for using alternative products.
• If you have any questions, please speak to your customer service advisor or your ICS Manager for further support.